Mylan NV (MYL)

MYL (NASDAQ:Pharmaceuticals: Generic) EQUITY
pos +0.00
Today's Range: 37.62 - 38.40 | MYL Avg Daily Volume: 4,668,400
Last Update: 08/17/18 - 4:00 PM EDT
Volume: 0
YTD Performance: -9.83%
Open: $0.00
Previous Close: $37.85
52 Week Range: $29.53 - $47.82
Oustanding Shares: 515,567,000
Market Cap: 19,514,210,938
6-Month Chart
TheStreet Ratings Grade for MYL
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 8 9 9 10
Moderate Buy 3 1 1 1
Hold 5 6 6 6
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.78 1.78 1.78 1.74
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 44.01
Price Earnings Comparisons:
MYL Sector Avg. S&P 500
44.01 43.98 19.40
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-4.82% 24.84% -31.25%
Revenue 7.06 0.50 0.15
Net Income 38.30 -0.20 -0.09
EPS 41.30 -0.50 -0.19
Earnings for MYL:
Revenue 11.91B
Average Earnings Estimates
Qtr (09/18) Qtr (12/18) FY (12/18) FY (12/19)
Average Estimate $1.21 $1.43 $4.68 $5.23
Number of Analysts 8 6 9 9
High Estimate $1.28 $1.54 $4.78 $5.54
Low Estimate $1.15 $1.31 $4.55 $4.90
Prior Year $1.10 $1.43 $4.56 $4.68
Growth Rate (Year over Year) 9.66% -0.12% 2.70% 11.72%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
Aug 09, 2018 | 8:01 AM EDT
Mylan was downgraded to "outperform" at Raymond James with a $44 price target.
The erratic CEO and awful fundamentals make it impossible to value TSLA -- despite attractive technicals.
While the move higher for crude prices late Tuesday took the energy sector with it, defense and aerospace names saw benefit as well.
Mar 06, 2018 | 10:01 AM EST
Mylan (MYL) was upgraded to "overweight" at Morgan Stanley with a $50 price target.
Subscriber Comment of the Day (Part Deux):
Gains are being left on the table as firms and investors let their politics or social concerns get the better of them.
I'm seeing some weakness in generic-drug stocks -- i.e., Teva Pharmaceuticals (TEVA) , Mylan (MYL) and Mallinckrodt (MNK) -- based on a New York Times article that hospitals might move into the generic-drug business.

Staying Liquid Real Money Pro($)

I missed very little and was better served at my "liquid" lunch meeting.

Mid-Afternoon Observations Real Money Pro($)

Some mid afternoon observations:   * Small yield flattening in today's session and little change in bond yields. * High yield is sl…

Here's What's Up This A.M. Real Money Pro($)

The Nasdaq (QQQs) turn slightly negative as most of the FANGs reverse lower.   Retail, generics (Teva (TEVA) and Mylan (MYL) ), big…

Columnist Conversations noted significant insider purchases in the beat-up shares of Newell (NWL). The stock is...
CEO Christian Brickman couldn't resist owning more Sally Beauty Holdings (SBH) when it briefly went below $14 ...
Move over Boca Biff - there is a new sheriff in town...Chance Walker! My conversation with Chance - high abov...
Oil tested its 200-day moving average this week, but the June 18 low of $63.59 a barrel held. As a result, we...


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.